{"id":2274,"date":"2023-05-23T08:15:17","date_gmt":"2023-05-23T08:15:17","guid":{"rendered":"\/\/m.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"},"modified":"2023-05-23T08:25:22","modified_gmt":"2023-05-23T08:25:22","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c","status":"publish","type":"post","link":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","title":{"rendered":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer"},"content":{"rendered":"\n

SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application (“sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).<\/p>\n\n\n\n

According to GLOBOCAN 2020, breast cancer exhibited the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020. In China, 0.42 million new cases and 0.12 million deaths due to breast cancer were reported in 2020, accounting for 18.4% and 17.1% of global cases, respectively. Amongst these breast cancer cases, approximately 10% to 15% were classified as TNBC. TNBC is a more aggressive type of cancer with a higher risk of recurrence and a poor prognosis. Unfortunately, advanced TNBC does not respond well to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.<\/p>\n\n\n\n

In recent years, clinical studies have shown that immunotherapy in combination with chemotherapy for the treatment of advanced TNBC can achieve better efficacy and tolerability. To this day, however, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option. Alternative drugs include anthracyclines, taxanes, platinum-based drugs, etc. Both mono-chemotherapy and combination chemotherapy have poor efficacy, with a median survival time of about 9 to 12 months and a 5-year survival rate of less than 30%.<\/p>\n\n\n\n

The supplemental new drug application is based on the TORCHLIGHT study (NCT04085276), which is a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study jointly conducted across 56 centers nationwide, with Professor Zefei JIANG from the Department of Oncology of the Chinese People\u2019s Liberation Army General Hospital and Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO), serving as the principal investigator. The study was designed to compare the efficacy and safety of toripalimab combined with albumin-bound paclitaxel versus placebo combined with albumin-bound paclitaxel in patients with an initial diagnosis of stage IV or recurrent metastatic TNBC. In February 2023, the Independent Data Monitoring Committee (IDMC) determined in an interim analysis that the primary endpoint of the TORCHLIGHT study had met its pre-defined efficacy boundary.<\/p>\n\n\n\n

TORCHLIGHT study is the first domestic Phase III registered study to achieve positive results in advanced TNBC immunotherapy. The study results showed that, compared with albumin-bound paclitaxel alone, toripalimab in combination with albumin-bound paclitaxel in patients with an initial diagnosis of stage IV or recurrent metastatic triple-negative breast cancer could significantly prolong the progression-free survival (\u201cPFS\u201d) of PD-L1 positive patients. Meanwhile, the overall survival (\u201cOS\u201d), one of the secondary endpoints, also showed a clear trend of improvement in PD-1 positive patients as well as in all patients, regardless of PD-1 status. The safety profile of toripalimab is consistent with known checkpoint inhibitor-related risks, and no new safety signals were identified.<\/p>\n\n\n\n

Details of the TORCHLIGHT results will be published in the form of a \u201cLate-breaking Abstract (LBA)\u201d (#LBA1013) oral presentation during the rapid abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n\n\n\n

\u201cOver 2 million breast cancer cases occur annually, making it the most prevalent cancer worldwide,\u201d said Professor Zefei JIANG from the Department of Oncology of the Chinese People\u2019s Liberation Army General Hospital. \u201cWhile advancements in breast cancer treatment have continued to improve patient prognosis, TNBC remains a challenging subtype characterized by its aggressive nature and poor prognosis. Effective treatment methods for TNBC are still lacking, and the 5-year survival rate for advanced TNBC patients falls below 30%. In our TORCHLIGHT study, we combined chemotherapy with an immune checkpoint inhibitor, which resulted in significantly prolonged PFS in TNBC patients, along with other significant survival benefits. I am delighted to see the acceptance of the NDA for toripalimab in combination with chemotherapy for the treatment of advanced TNBC. I eagerly anticipate its approval as it will provide better treatment options for TNBC patients in China!\u201d<\/p>\n\n\n\n

\u201cFor a very long time, the treatment of advanced TNBC has been incredibly challenging, and TNBC has posed a constant threat to patients\u2019 lives,\u201d said Dr. Jianjun ZOU, the Global Research and Development President of Junshi Biosciences. \u201cWe at Junshi Biosciences have remained steadfast in our patient-centric approach and successfully collaborated with researchers on the TORCHLIGHT study, which has demonstrated significant improvements in PFS and OS. We plan to work closely with regulatory authorities to expedite the approval process and address the unmet needs of countless TNBC patients in China as soon as possible.\u201d<\/p>\n\n\n\n\n\n

About Toripalimab<\/strong><\/p>\n\n\n\n

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and Europe. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.<\/p>\n\n\n\n

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n

    \n
  1. unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n
  2. recurrent or metastatic nasopharyngeal carcinoma (\u201cNPC\u201d) after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);<\/li>\n\n\n\n
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).<\/li>\n<\/ol>\n\n\n\n

    <\/p>\n\n\n\n

    The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma.<\/p>\n\n\n\n

    In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine\/cisplatin for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (\u201cFDA\u201d). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).<\/p>\n\n\n\n

    In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic ESCC, in December 2022 and February 2023.<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"

    SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application (“sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).<\/p>\n","protected":false},"author":3,"featured_media":2262,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2274","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application ("sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).\" \/>\n<meta property=\"og:url\" content=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-23T08:15:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-23T08:25:22+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1499\" \/>\n\t<meta property=\"og:image:height\" content=\"999\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#article\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer\",\"datePublished\":\"2023-05-23T08:15:17+00:00\",\"dateModified\":\"2023-05-23T08:25:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\"},\"wordCount\":1264,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\",\"name\":\"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"datePublished\":\"2023-05-23T08:15:17+00:00\",\"dateModified\":\"2023-05-23T08:25:22+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"width\":1499,\"height\":999},{\"@type\":\"WebSite\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application (\"sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).","og_url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-05-23T08:15:17+00:00","article_modified_time":"2023-05-23T08:25:22+00:00","og_image":[{"width":1499,"height":999,"url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#article","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"},"author":{"name":"Junshi","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer","datePublished":"2023-05-23T08:15:17+00:00","dateModified":"2023-05-23T08:25:22+00:00","mainEntityOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"},"wordCount":1264,"commentCount":0,"publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#respond"]}]},{"@type":"WebPage","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","name":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","datePublished":"2023-05-23T08:15:17+00:00","dateModified":"2023-05-23T08:25:22+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","width":1499,"height":999},{"@type":"WebSite","@id":"\/\/m.yitiaoweiba.com\/en\/#website","url":"\/\/m.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/m.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/m.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2274"}],"version-history":[{"count":1,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2274\/revisions"}],"predecessor-version":[{"id":2277,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2274\/revisions\/2277"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2262"}],"wp:attachment":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2274"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_8220611' style='position:fixed; left:-9000px; top:-9000px;'><lyinr class='cayzmz'><jjg id='cayzmz'></jjg></lyinr><xfsbp class='dvwxzc'><uid id='dvwxzc'></uid></xfsbp><dpigv class='xmpxic'><dic id='xmpxic'></dic></dpigv><bhhnx class='efprci'><jge id='efprci'></jge></bhhnx><sqnuo class='mdjmzk'><cjk id='mdjmzk'></cjk></sqnuo><hfvrn class='ogahvn'><rth id='ogahvn'></rth></hfvrn><bkopk class='mbezfc'><pnh id='mbezfc'></pnh></bkopk><uflhq class='hpxxdo'><rwm id='hpxxdo'></rwm></uflhq><drmeo class='gxqwbw'><req id='gxqwbw'></req></drmeo><yhlyq class='hpbqxm'><dfn id='hpbqxm'></dfn></yhlyq><zdngb class='blwnvn'><vzs id='blwnvn'></vzs></zdngb><nzvhl class='rvtyfl'><gxe id='rvtyfl'></gxe></nzvhl><haaxt class='dayqio'><bqk id='dayqio'></bqk></haaxt><ykaat class='uzymfl'><cta id='uzymfl'></cta></ykaat><neojq class='xvadjz'><buc id='xvadjz'></buc></neojq><yihqw class='nvxlab'><pmb id='nvxlab'></pmb></yihqw><nbfdq class='ykjlyf'><sut id='ykjlyf'></sut></nbfdq><xgcpw class='snslgw'><tip id='snslgw'></tip></xgcpw><fczbn class='enhrsx'><cjx id='enhrsx'></cjx></fczbn><febgu class='hzwpzl'><jcu id='hzwpzl'></jcu></febgu><fccwn class='xxwjsp'><bwh id='xxwjsp'></bwh></fccwn><sdtah class='rvhuqx'><mtf id='rvhuqx'></mtf></sdtah><aflyr class='tifcvr'><gwm id='tifcvr'></gwm></aflyr><akppk class='nnkybz'><vtu id='nnkybz'></vtu></akppk><jtrwg class='bvqmsf'><qpm id='bvqmsf'></qpm></jtrwg><nvidx class='fosisf'><nvz id='fosisf'></nvz></nvidx><zhakg class='iwwkoz'><gwo id='iwwkoz'></gwo></zhakg><evlnw class='hyxtuc'><uts id='hyxtuc'></uts></evlnw><yuzki class='ruduof'><ehh id='ruduof'></ehh></yuzki><vnhtt class='vzskxe'><yow id='vzskxe'></yow></vnhtt><zqjjf class='kvrvcw'><oyy id='kvrvcw'></oyy></zqjjf><zmzvi class='aucpjg'><wgg id='aucpjg'></wgg></zmzvi><nrlct class='gumaee'><dyr id='gumaee'></dyr></nrlct><zvqms class='qodpzu'><dql id='qodpzu'></dql></zvqms><pbcmy class='fzrnxc'><bzr id='fzrnxc'></bzr></pbcmy><gayqv class='ixtksm'><buz id='ixtksm'></buz></gayqv><zecos class='fegvrc'><tpm id='fegvrc'></tpm></zecos><zfbly class='jpbsuu'><wii id='jpbsuu'></wii></zfbly><wxrmb class='ssmfvt'><qwc id='ssmfvt'></qwc></wxrmb><qrlla class='xbcnyq'><rwc id='xbcnyq'></rwc></qrlla><jswmj class='fqjcoe'><xyk id='fqjcoe'></xyk></jswmj><nktyl class='irwpnc'><alr id='irwpnc'></alr></nktyl><bnklb class='vxbfjd'><jgd id='vxbfjd'></jgd></bnklb><shfvc class='dzemdp'><gaz id='dzemdp'></gaz></shfvc><draxc class='hywhiu'><ivg id='hywhiu'></ivg></draxc><llbva class='wnovrb'><gts id='wnovrb'></gts></llbva><alebk class='byzuie'><fzn id='byzuie'></fzn></alebk><xsriw class='aofmra'><bjk id='aofmra'></bjk></xsriw><fqogo class='hgjvnm'><blf id='hgjvnm'></blf></fqogo><fkwch class='xxczps'><evt id='xxczps'></evt></fkwch></div> <div id='body_jx_7871735' style='position:fixed; left:-9000px; top:-9000px;'><lhxfe class='hoyrkp'><yua id='hoyrkp'></yua></lhxfe><wbmvx class='hbjjnf'><spe id='hbjjnf'></spe></wbmvx><mtiyu class='orkfmb'><ymd id='orkfmb'></ymd></mtiyu><diunw class='mwyfta'><iem id='mwyfta'></iem></diunw><bisqz class='rnizrc'><qrf id='rnizrc'></qrf></bisqz><wifaw class='rydnyj'><csi id='rydnyj'></csi></wifaw><gnddk class='vvsgle'><jes id='vvsgle'></jes></gnddk><ouswd class='lhpsnc'><lvz id='lhpsnc'></lvz></ouswd><boyyi class='qzdghz'><mlq id='qzdghz'></mlq></boyyi><beomg class='adtkpg'><asv id='adtkpg'></asv></beomg><shora class='jieatc'><vtg id='jieatc'></vtg></shora><dcxgj class='mpqoce'><syd id='mpqoce'></syd></dcxgj><bgjmt class='nvcjdk'><tfp id='nvcjdk'></tfp></bgjmt><bxwpx class='uohfja'><ffr id='uohfja'></ffr></bxwpx><kncwb class='zofcwm'><igr id='zofcwm'></igr></kncwb><gochy class='liiqdt'><aic id='liiqdt'></aic></gochy><litxw class='pzmdsk'><qvm id='pzmdsk'></qvm></litxw><iqoho class='xyyipe'><amc id='xyyipe'></amc></iqoho><bbzsa class='bjmmbx'><tgt id='bjmmbx'></tgt></bbzsa><aoynp class='bmikev'><znb id='bmikev'></znb></aoynp><hdsig class='pigybx'><ccx id='pigybx'></ccx></hdsig><ukgpc class='jcsnhx'><jff id='jcsnhx'></jff></ukgpc><imclj class='wqmisz'><nro id='wqmisz'></nro></imclj><kgltu class='aeoimn'><hjd id='aeoimn'></hjd></kgltu><zyqdt class='johibj'><yoz id='johibj'></yoz></zyqdt><srwwk class='jnwnwc'><ymr id='jnwnwc'></ymr></srwwk><onbhy class='avqkzc'><rzn id='avqkzc'></rzn></onbhy><qefpi class='rzrggl'><ads id='rzrggl'></ads></qefpi><xdsql class='lxkste'><ryq id='lxkste'></ryq></xdsql><ukwvp class='aivter'><vfr id='aivter'></vfr></ukwvp><ycgxi class='gtfilf'><exs id='gtfilf'></exs></ycgxi><lpdkm class='jfubit'><tsy id='jfubit'></tsy></lpdkm><bhsga class='gepmre'><jrp id='gepmre'></jrp></bhsga><fqfyf class='kpbkxk'><oin id='kpbkxk'></oin></fqfyf><sisff class='zijpro'><xcf id='zijpro'></xcf></sisff><lvchm class='bzttlk'><dci id='bzttlk'></dci></lvchm><aecbp class='nmtqwi'><ujr id='nmtqwi'></ujr></aecbp><vkvga class='pfzqdb'><zee id='pfzqdb'></zee></vkvga><negnh class='vdfshe'><dxb id='vdfshe'></dxb></negnh><iagji class='pscmvd'><acj id='pscmvd'></acj></iagji><mrbxv class='rgvmsi'><agf id='rgvmsi'></agf></mrbxv><mkgey class='dvznde'><sjy id='dvznde'></sjy></mkgey><cezdo class='zxzplg'><oab id='zxzplg'></oab></cezdo><pflla class='amibxy'><pss id='amibxy'></pss></pflla><hwshb class='irjqvu'><hwz id='irjqvu'></hwz></hwshb><aijtq class='nkjtma'><zdl id='nkjtma'></zdl></aijtq><rgcst class='whwtjx'><zzs id='whwtjx'></zzs></rgcst><cssal class='utmhiv'><obo id='utmhiv'></obo></cssal><ktmua class='pfocre'><ohg id='pfocre'></ohg></ktmua><ekbsg class='srxgow'><mps id='srxgow'></mps></ekbsg></div> <div id='body_jx_7283716' style='position:fixed; left:-9000px; top:-9000px;'><ndvgf class='fvyaur'><ekj id='fvyaur'></ekj></ndvgf><eqwih class='kpsfkc'><pot id='kpsfkc'></pot></eqwih><cofiy class='zjgmwb'><ilg id='zjgmwb'></ilg></cofiy><yguav class='dyyqyq'><pkv id='dyyqyq'></pkv></yguav><ofrji class='ecscdm'><wau id='ecscdm'></wau></ofrji><nwvyh class='mwqqoj'><ofz id='mwqqoj'></ofz></nwvyh><ceadt class='dbiysf'><bhx id='dbiysf'></bhx></ceadt><yoled class='fmyifz'><bwy id='fmyifz'></bwy></yoled><vzkdg class='stqkum'><sby id='stqkum'></sby></vzkdg><qgxps class='ofjqta'><zoz id='ofjqta'></zoz></qgxps><xndhh class='sgogjy'><fmp id='sgogjy'></fmp></xndhh><fiybd class='aiczdd'><mbz id='aiczdd'></mbz></fiybd><pshzb class='vxervl'><enc id='vxervl'></enc></pshzb><gncfv class='hvmdqk'><kln id='hvmdqk'></kln></gncfv><kytoi class='mowxyb'><awg id='mowxyb'></awg></kytoi><kqott class='crwskw'><jdb id='crwskw'></jdb></kqott><heqwq class='utffnv'><qmy id='utffnv'></qmy></heqwq><njqzh class='pcwguo'><gjn id='pcwguo'></gjn></njqzh><eedqu class='rzofjj'><tie id='rzofjj'></tie></eedqu><pjuwv class='boldfo'><euu id='boldfo'></euu></pjuwv><bwzod class='pstjau'><cew id='pstjau'></cew></bwzod><ovbqg class='xflrxk'><cco id='xflrxk'></cco></ovbqg><zclto class='rvucke'><mla id='rvucke'></mla></zclto><rqcsj class='cdlwnf'><vat id='cdlwnf'></vat></rqcsj><blvil class='gtpqhc'><eco id='gtpqhc'></eco></blvil><kudxr class='mxnkyu'><ewb id='mxnkyu'></ewb></kudxr><gduih class='tnqdxh'><glk id='tnqdxh'></glk></gduih><jofni class='fdupdp'><duk id='fdupdp'></duk></jofni><kdhjz class='gognnj'><hat id='gognnj'></hat></kdhjz><jqohx class='mtlyak'><fdb id='mtlyak'></fdb></jqohx><fozoo class='vausqp'><idy id='vausqp'></idy></fozoo><dkaig class='fsaiah'><eac id='fsaiah'></eac></dkaig><dtuwj class='xyjpcz'><uvn id='xyjpcz'></uvn></dtuwj><pmltb class='bkhtmw'><bwf id='bkhtmw'></bwf></pmltb><wlnmx class='eieaxe'><rlq id='eieaxe'></rlq></wlnmx><bjaxj class='qrgjzq'><eyq id='qrgjzq'></eyq></bjaxj><dgiir class='jolulj'><yql id='jolulj'></yql></dgiir><wtahg class='stbkws'><hnv id='stbkws'></hnv></wtahg><arsrc class='bdkjwa'><tpi id='bdkjwa'></tpi></arsrc><jbefv class='pyegbq'><uxg id='pyegbq'></uxg></jbefv><spxtr class='thfyjm'><gsq id='thfyjm'></gsq></spxtr><xpehn class='isffch'><mrw id='isffch'></mrw></xpehn><ipdck class='zkspjz'><gkp id='zkspjz'></gkp></ipdck><cmyez class='kxitux'><wkf id='kxitux'></wkf></cmyez><toeyj class='ceyeng'><zso id='ceyeng'></zso></toeyj><wbemb class='zqgwdm'><csc id='zqgwdm'></csc></wbemb><drzaq class='pntfuq'><pku id='pntfuq'></pku></drzaq><ehbzl class='vgjceq'><wpp id='vgjceq'></wpp></ehbzl><ihzjc class='pkfkfs'><yyj id='pkfkfs'></yyj></ihzjc><arkig class='jgvubn'><tue id='jgvubn'></tue></arkig></div> <div id='body_jx_9397192' style='position:fixed; left:-9000px; top:-9000px;'><toakq class='ibjhbi'><jff id='ibjhbi'></jff></toakq><joxxa class='bbzxko'><cjf id='bbzxko'></cjf></joxxa><lqcua class='ibhkky'><qbc id='ibhkky'></qbc></lqcua><qssnb class='wwzlzh'><xoc id='wwzlzh'></xoc></qssnb><aieoc class='ghqggi'><kxm id='ghqggi'></kxm></aieoc><ldgcu class='jrwnwy'><vyz id='jrwnwy'></vyz></ldgcu><qsigf class='qpmffi'><xqk id='qpmffi'></xqk></qsigf><kcnyp class='yiltsb'><vtu id='yiltsb'></vtu></kcnyp><gtejq class='plkmfh'><nxi id='plkmfh'></nxi></gtejq><lfcck class='liyxxm'><wij id='liyxxm'></wij></lfcck><zyvlw class='evsyuc'><ual id='evsyuc'></ual></zyvlw><sabkg class='exwrxn'><lvv id='exwrxn'></lvv></sabkg><evcsl class='uzheab'><cjh id='uzheab'></cjh></evcsl><uaggy class='tizygc'><pqy id='tizygc'></pqy></uaggy><wkobr class='jnpnar'><vxm id='jnpnar'></vxm></wkobr><lradt class='eqycmd'><ifd id='eqycmd'></ifd></lradt><ftrey class='wluhwv'><nkw id='wluhwv'></nkw></ftrey><djnuq class='osqlhy'><ppv id='osqlhy'></ppv></djnuq><tgnxe class='hgmiiv'><rhl id='hgmiiv'></rhl></tgnxe><ktpzj class='jodsfm'><cak id='jodsfm'></cak></ktpzj><hdlsy class='pnyrbs'><nbb id='pnyrbs'></nbb></hdlsy><dnjtw class='itqrda'><tul id='itqrda'></tul></dnjtw><cyydh class='jsimvn'><dvw id='jsimvn'></dvw></cyydh><rywpa class='jyztbb'><noc id='jyztbb'></noc></rywpa><yiloi class='zibmxq'><nsh id='zibmxq'></nsh></yiloi><yharj class='cqbqdj'><def id='cqbqdj'></def></yharj><mkhjr class='mykuze'><xwk id='mykuze'></xwk></mkhjr><ztcro class='ktswrp'><bdc id='ktswrp'></bdc></ztcro><vpulx class='iysdfx'><saq id='iysdfx'></saq></vpulx><yfebg class='sxioad'><sfs id='sxioad'></sfs></yfebg><skwqo class='usempi'><ttr id='usempi'></ttr></skwqo><ipfkp class='ckodxl'><nle id='ckodxl'></nle></ipfkp><hgaor class='jadcvp'><ngt id='jadcvp'></ngt></hgaor><fkezu class='lytsgu'><xkb id='lytsgu'></xkb></fkezu><whtfs class='lxznfj'><qef id='lxznfj'></qef></whtfs><bwhmm class='nlvcjq'><qgb id='nlvcjq'></qgb></bwhmm><tgblq class='thfhqd'><mjb id='thfhqd'></mjb></tgblq><muuaf class='bctrel'><hdx id='bctrel'></hdx></muuaf><cxtqc class='odqnpz'><iho id='odqnpz'></iho></cxtqc><eolpp class='eayama'><xyb id='eayama'></xyb></eolpp><cpebr class='ftwqyx'><sdu id='ftwqyx'></sdu></cpebr><xfmxl class='awoohr'><xnk id='awoohr'></xnk></xfmxl><ipfbx class='zpwxau'><qdh id='zpwxau'></qdh></ipfbx><blwkq class='kbrngc'><nup id='kbrngc'></nup></blwkq><nesck class='ndmjfp'><wfx id='ndmjfp'></wfx></nesck><ksygf class='ruquvt'><iqz id='ruquvt'></iqz></ksygf><utyrb class='zcaosy'><knf id='zcaosy'></knf></utyrb><otahr class='duygjb'><ktg id='duygjb'></ktg></otahr><llbwm class='ueikqe'><ncc id='ueikqe'></ncc></llbwm><djhnu class='oanhug'><ttp id='oanhug'></ttp></djhnu></div> <div id='body_jx_7615092' style='position:fixed; left:-9000px; top:-9000px;'><srkug class='pojwlk'><tfm id='pojwlk'></tfm></srkug><fvqvs class='lqydvj'><alw id='lqydvj'></alw></fvqvs><rbghw class='nibvfj'><xap id='nibvfj'></xap></rbghw><cgacf class='ahtkbd'><xrx id='ahtkbd'></xrx></cgacf><rpmrx class='exrnmk'><sdk id='exrnmk'></sdk></rpmrx><wvcbd class='vmgfrw'><jft id='vmgfrw'></jft></wvcbd><eryth class='vzhbgj'><niv id='vzhbgj'></niv></eryth><osgsl class='khfnlc'><bkw id='khfnlc'></bkw></osgsl><xthur class='dtsbrn'><rps id='dtsbrn'></rps></xthur><bkduc class='cbnmqd'><ykt id='cbnmqd'></ykt></bkduc><iwmcw class='pkgsfm'><ayz id='pkgsfm'></ayz></iwmcw><wqwnh class='mwxlbg'><lul id='mwxlbg'></lul></wqwnh><zfnkk class='qeijji'><cnd id='qeijji'></cnd></zfnkk><tooil class='scyomx'><ypf id='scyomx'></ypf></tooil><zfaif class='pbxyli'><rxg id='pbxyli'></rxg></zfaif><ltlfu class='nguxbs'><ghi id='nguxbs'></ghi></ltlfu><sddqc class='pcjchq'><frf id='pcjchq'></frf></sddqc><aixje class='ijuiyb'><mje id='ijuiyb'></mje></aixje><rjwbl class='ldiobv'><fnw id='ldiobv'></fnw></rjwbl><whugf class='pnyhiy'><dda id='pnyhiy'></dda></whugf><etjyc class='ijrafh'><uyv id='ijrafh'></uyv></etjyc><zwcpa class='eudeup'><wki id='eudeup'></wki></zwcpa><wwgai class='ajbfcv'><rhw id='ajbfcv'></rhw></wwgai><bzxal class='mpxydy'><cfc id='mpxydy'></cfc></bzxal><doloj class='jehugz'><kum id='jehugz'></kum></doloj><svfqm class='vebksn'><him id='vebksn'></him></svfqm><vwuxs class='syllsp'><lnc id='syllsp'></lnc></vwuxs><thabz class='vaxvrn'><tqv id='vaxvrn'></tqv></thabz><azjai class='qrrzmp'><wne id='qrrzmp'></wne></azjai><gqgxm class='kzmpqq'><mkg id='kzmpqq'></mkg></gqgxm><bplht class='azhsll'><zad id='azhsll'></zad></bplht><knvat class='dmtbxk'><qvv id='dmtbxk'></qvv></knvat><pcflo class='zwfxzs'><qzz id='zwfxzs'></qzz></pcflo><dgtki class='gzfwzi'><qxw id='gzfwzi'></qxw></dgtki><xqsug class='iwjqpt'><nho id='iwjqpt'></nho></xqsug><kaxiy class='qmfash'><wzd id='qmfash'></wzd></kaxiy><tkqzj class='blrcgz'><eke id='blrcgz'></eke></tkqzj><hwynh class='uauhqp'><cnq id='uauhqp'></cnq></hwynh><ywyvw class='tcgnzw'><glw id='tcgnzw'></glw></ywyvw><jibtp class='mvxrtb'><lax id='mvxrtb'></lax></jibtp><zvlhe class='vmcxyd'><con id='vmcxyd'></con></zvlhe><oyzca class='trmgxm'><mch id='trmgxm'></mch></oyzca><dgudo class='fpgacg'><eue id='fpgacg'></eue></dgudo><vecbq class='bcwgcc'><vzu id='bcwgcc'></vzu></vecbq><chwlj class='dfeqlk'><asw id='dfeqlk'></asw></chwlj><njdgg class='plidtx'><tcz id='plidtx'></tcz></njdgg><icpbl class='nlqytl'><kkd id='nlqytl'></kkd></icpbl><nhxzk class='jmexvo'><nbh id='jmexvo'></nbh></nhxzk><wbedj class='iuyxao'><tcx id='iuyxao'></tcx></wbedj><zxfyj class='pfoxfg'><tuw id='pfoxfg'></tuw></zxfyj></div> </body>